Guardant Health, Inc. GH
Guardant Health, Inc. (Nasdaq: GH) is an oncology diagnostics company. Its next catalyst on record is Shield (SOLAR post-approval study): Study conclusion (2031).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Shield (SOLAR post-approval study) — Study conclusion (2031). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Shield (CRC screening) | colorectal cancer screening | — | NA_NON_THERAPEUTIC |
| Guardant360 CDx / Guardant360 Liquid CDx | advanced solid tumor profiling and companion diagnostic | — | NA_NON_THERAPEUTIC |
| Guardant360 Liquid and Tissue | advanced cancer therapy selection | — | NA_NON_THERAPEUTIC |
| Guardant Reveal | MRD / recurrence monitoring | — | NA_NON_THERAPEUTIC |
| Shield MCD (multi-cancer detection) | multi-cancer detection | — | NA_NON_THERAPEUTIC |
| Shield lung cancer screening (SHIELD LUNG) | lung cancer screening, high-risk ages 50-80 | — | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other oncology companies
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- NovoCure Ltd NVCR
- Personalis, Inc. PSNL
- AnaptysBio, Inc. ANAB
- Freenome, Inc. FRNM
- Alpha Tau Medical Ltd. DRTS
- Castle Biosciences Inc CSTL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.